British American Tobacco p.l.c.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From British American Tobacco p.l.c.
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
Roy Jakobs was appointed internally to head connected care at Philips on 28 January, shortly before COVID-19 forced the first of many lockdowns around the world. The disruption prompted a rapid rethink of priorities, which has shown opportunities for lasting health care system change.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
- Other Names / Subsidiaries
- Kentucky BioProcessing (KBP)
- Nicovations Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.